CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.

Cyclin B2 (CCNB2) is an important component of the cyclin pathway and plays a key role in the occurrence and development of cancer. However, the correlation between prognosis of low-grade glioma (LGG), CCNB2, and tumor infiltrating lymphocytes is not clear. The expression of CCNB2 in LGG was queried in Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and TIMER databases. The relationships between CCNB2 and the clinicopathological features of LGG were analyzed using the Chinese Glioma Genome Atlas (CGGA) database. The relationship between CCNB2 expression and overall survival (OS) was evaluated by GEPIA2. The correlation between CCNB2 and LGG immune infiltration was analyzed by the TIMER database. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect CCNB2 expression. The expression of CCNB2 differed across different tumor tissues, but was higher in LGG than in normal tissues. LGG patients with high expression of CCNB2 have poorer prognosis. The expression of CCNB2 was correlated with age, WHO grade, IDH mutational status, 1p/19q codeletion status, and other clinicopathological features. The expression of CCNB2 in LGG was positively correlated with the infiltration level of B cells, dendritic cells, and macrophages. qRT-PCR results revealed that the expression of CCNB2 in LGG tissues was higher than normal tissues and higher expression of CCNB2 was associated with worse prognosis. CCNB2 may be used as a potential biomarker to determine the prognosis of LGG and is also related to immune infiltration. © 2022 The Author(s).

Citation

Dengfeng Wang, Hongjiao Sun, Xiaohui Li, Gang Wang, Guizhong Yan, Haijun Ren, Boru Hou. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma. Bioscience reports. 2022 Jan 28;42(1)

Mesh Tags

Substances

PMID: 34908101

search → result